Experimental scrutiny and project timelines : an example

Dooley, N. and Ford, S. J. and Prasad, Elke and Elliott, M. and Halbert, Gavin (2010) Experimental scrutiny and project timelines : an example. Journal of Pharmacy and Pharmacology, 62 (10). pp. 1208-1209. ISSN 0022-3573 (https://doi.org/10.1111/j.2042-7158.2010.01178.x)

Preview

PDF. Filename: Poster_APS_Nottingham_2010.pdf Accepted Author Manuscript Download (555kB)| Preview

Abstract

AZD0424 (Fig. 1) is a dual selective inhibitor of Src and Abl non-receptor tyrosine kinases being developed for clinical trial through a partnership between AstraZeneca and Cancer Research UK. Formulation, pre-formulation and development studies were performed at the Cancer Research UK Formulation Unit at the University of Strathclyde. Here the authors report an example where the proper use and interpretation of ‘forced degradation’ experiments (performed during the early development stages of a drug project) allowed analysts to quickly identify problems occurring at subsequent stages.

• Share and Export
  

  RDF+XMLBibTeXRIOXX2 XMLRDF+N-TriplesJSONDublin CoreAtomSimple MetadataReferMETSHTML CitationASCII CitationOpenURL ContextObjectEndNoteOpenURL ContextObject in SpanMODSMPEG-21 DIDLEP3 XMLData Cite XMLRIS (EndNote Online, Zotero, Ref manager, etc)RDF+N3Multiline CSV
• Item metadata

  Item type:	Article
  ID code:	37133
  Dates:	Date Event October 2010 Published
  Notes:	ABSTRACTS FROM THE UK-PHARMSCI CONFERENCE, 1–3 SEPTEMBER 2010
  Subjects:	Medicine > Therapeutics. Pharmacology
  Department:	Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
  Depositing user:	Pure Administrator
  Date deposited:	26 Jan 2012 16:09
  Last modified:	08 Apr 2024 19:46
  URI:	https://strathprints.strath.ac.uk/id/eprint/37133